RedHill Biopharma Secures $10.5 Million Judgment Win

RedHill Biopharma ( (RDHL) ) has provided an announcement.

RedHill Biopharma announced that the New York Supreme Court’s judgment in favor of the company against Kukbo Co. Ltd is now final and enforceable, with no further appeals possible. The court awarded RedHill over $10.5 million, including $8.6 million in the main judgment and $1.9 million for legal fees and expenses, with interest continuing to accrue. Additionally, RedHill secured a Korean court attachment to prevent Kukbo from disposing of assets before judgment enforcement, potentially strengthening RedHill’s financial position and market confidence.

The most recent analyst rating on (RDHL) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.

Spark’s Take on RDHL Stock

According to Spark, TipRanks’ AI Analyst, RDHL is a Underperform.

RedHill Biopharma’s overall stock score is primarily impacted by its challenging financial performance, marked by consistent losses and high leverage. Technical analysis further indicates bearish momentum, while the lack of valuation metrics adds uncertainty. The absence of earnings call insights and corporate events means these factors do not influence the score.

To see Spark’s full report on RDHL stock, click here.

More about RedHill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology, primarily in the U.S. market. The company promotes Talicia®, an FDA-approved drug for Helicobacter pylori infection, and has several late-stage development programs targeting various conditions, including COVID-19, Crohn’s disease, and cancer.

Average Trading Volume: 1,378,271

Technical Sentiment Signal: Sell

Current Market Cap: $4.23M

Learn more about RDHL stock on TipRanks’ Stock Analysis page.